The Abliva team invites you to a conference call to discuss the positive outcome of the interim analysis for FALCON, the potentially registrational study evaluating KL1333 in patients with primary mitochondrial disease. The study evaluates fatigue and myopathy as alternative independent primary endpoints, only one of which is required for a successful study readout.

The DMC recommended continuing the study without modification and confirmed that both primary endpoints have passed futility. The favorable recommendation by the DMC to continue the FALCON study with a total of 180 patients validates the overall study design and confirms the strong safety profile of KL1333.

The event will provide additional details on the FALCON study and the interim analysis. A live question and answer session will follow the formal presentation.